Lipid nanoparticles in the treatment of lung cancer-hype or hope?

Lung cancer is still one of the most common cancer entities worldwide and the leading cause of cancer mortality. Despite significant advances in the diagnosis and therapy of lung cancer, many patients do not respond to existing therapies, indicating an urgent need for the development of novel treatment strategies. In recent years, nanotechnology has led to significant progress in modern medicine. Especially lipid nanoparticles (LNPs) evoked substantial interest, due to their broad application as coronavirus disease 2019 (COVID-19) vaccines. In the future of lung cancer treatment, lipid nanoparticles hold the potential to provide specific, safe, and well-tolerated treatments by incorporating multiple drugs and targeting agents and enabling their trafficking to tissues or cell types of interest. This review briefly summarizes the application of LNPs in lung cancer treatment as well as their future possibilities.